Back

Incidence rates of oedema with triple therapy amlodipine/valsartan/HCTZ as compared to valsartan/amlodipine and valsartan/HCTZ dual combination therapy

26 August 2018 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster Session 2 - Hypertension treatment old and new Pharmacotherapy ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Rainer Duesing

Hypertoniezentrum Bonn, Bonn (Germany)

9 More presentations in this session

Presentation thumbnail
Doctor E. Kocianova (Olomouc, CZ)
Abstract Slides
Presentation thumbnail
Professor N. Izmozherova (Yekaterinburg, RU)
Abstract
Presentation thumbnail
Doctor A. Farcas (Cluj Napoca, RO)
Abstract
Presentation thumbnail
Professor Y. Takeda (Uchinada, JP)
Abstract Slides
Presentation thumbnail
Doctor T. Netchessova (Minsk, BY)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 2 - Hypertension treatment old and new

The Event

Event poster

ESC Congress 2018

26 August 2018 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Dynamics of indicators of central hemodynamics and arterial wall rigidity during the background of combination therapy with amlodipine/ valsartan in patients with arterial hypertension
25 August 2023
thumbnail
Congress Presentation
Risk of hyperkalemia with sacubitril/valsartan vs. RAAS inhibitor use in heart failure with reduced and preserved ejection fraction: a meta-analysis of 6 RCTs including 17,362 patients
29 June 2021
thumbnail
Congress Presentation
Successful perindopril/amlodipine+indapamide treatment as second line in uncontrolled hypertensive patients in line with european guidelines
7 April 2022
thumbnail
Congress Presentation
Add-on treatment with zilebesiran for inadequately controlled hypertension: KARDIA-2 RCT
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources